Skip to NavigationSkip to content

Eli Lilly's Taltz shows superiority over AbbVie's Humira

Published on 18/12/18 at 11:14am

A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naïve when compared to AbbVie's Humira.

 The Phase IIIb/IV SPIRIT-H2H study, 566 patients with active PsA demonstrates Taltz’s superiority over the world’s bestselling drug.

Lotus Mallbris, vice president of immunology development at the Indian-based firm suggested that “these results provide evidence that Taltz can be used as a first-line biologic treatment for patients with active psoriatic arthritis.”

Last month Eli Lilly revealed that sales of Taltz for the third quarter of this year shot up by as much as 74 percent year-over-year increasing to a total of $263.9 million, beating forecasts. Overall, the IL-17 inhibitor had total revenue of $560 million in 2017.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches